Article

CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 variants

2021-05-15

Abstract excerpt

SARS-CoV-2 and its variants are raging worldwide. Unfortunately, the global vaccination is not efficient enough to attain a vaccine-based herd-immunity and yet no special and effective drug is developed to contain the spread of the disease. Previously we have identified CD147 as a novel receptor for SARS-CoV-2 infection. Here, we demonstrated that CD147 antibody effectively inhibits infection and cytokine storm ca...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b92924d3-1eda-5ecc-9896-eff89304198b
DOI: 10.1101/2021.05.14.444111

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 variantsDOI 10.1101/2021.05.14.444111Read

Identifying epitopes for cluster of differentiation and design of new peptides inhibitors against human SARS-CoV-2 spike RBD by an in-silico approachSemantic proximity Read

Development of a Novel Human CD147 Knock-in NSG Mouse Model to Test SARS-CoV-2 Viral InfectionSemantic proximity Read

Development of a Novel Human CD147 Transgenic NSG Mouse Model to test SARS-CoV-2 Infection and Immune ResponsesSemantic proximity Read

Quantitative Insight into Immunopathology of SARS-CoV-2 Infection.Semantic proximity Read

Distribution of ACE2, CD147, cyclophilins, CD26 and other SARS-CoV-2 associated molecules in human tissues and immune cells in health and diseaseSemantic proximity Read

SARS-CoV-2-associated lymphopenia: possible mechanisms and the role of CD147Semantic proximity Read

Molecular basis of the potential interaction of SARS-CoV-2 spike protein to CD147 in COVID-19 associated-lymphopeniaSemantic proximity Read

A vimentin-targeting oral compound with host-directed antiviral and anti-inflammatory actions addresses multiple features of COVID-19 and related diseasesSemantic proximity Read

Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trialSemantic proximity Read

Can we Succeed in the Fight Against SARS-CoV-2 with its Emerging New Variants?Semantic proximity Read

COVID-19 patients have increased levels of membrane-associated and soluble CD48Semantic proximity Read

Impact of BSG/CD147 gene expression on diagnostic, prognostic and therapeutic strategies towards malignant cancers and possible susceptibility to SARS-CoV-2Semantic proximity Read